study on mastocytosis for rupatadine treatment

Conditions: Mastocytosis

Summary: study title: an exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg rupatadine on the treatment of mastocytosis symptoms. study code: smart-2010-1 principal investigator, co-investigator, sponsor, and study centre (acc. to § 40 abs. 4 amg) dr. med. f. siebenhaar, prof. dr. med. m. maurer, allergie-centrum-charité, department of dermatology and allergy, charité - universitätsmedizin berlin, charitéplatz 1, d-10117 berlin biometry and biostatistical analyses division of biostatistics and clinical epidemiology, charité - universitätsmedizin berlin, charitéplatz 1, d-10117 berlin monitoring coordination centre for clinical studies (kks), charité - universitätsmedizin berlin, charitéplatz 1, d-10117 berlin clinical phase phase ii primary objective: reduction of wheal and flare type skin reaction after standardised provocation testing assessed by volumetric and thermographic measurements. secondary objectives: improvement of additional related symptoms (e.g. pruritus) and subjective affliction as assessed by symptom score, dlqi, itchy-qol and vas. study design: an exploratory, randomised, double-blind, placebo controlled crossover study type and number of patients: male and female patients (n = 30) with cutaneous mastocytosis and indolent systemic mastocytosis with skin involvement main criteria for inclusion: mastocytosis patients aged 18-65 years, signed written consent, no systemic corticosteroid or other immunosuppressive therapy, no permanent severe diseases test product, dose and mode of administration 20 mg rupatadine or placebo before provocation testing, oral administration (tablets) duration of treatment: 28 days (testing will be done at the day of last treatment) assessment of efficacy: 1. assessment of wheal and flare development by planimetric analyses of digital photographic, volumetric, and thermographic imaging (time lapse) before and after treatment with study medication, 2. additional assessment of symptoms, 3. assessment of life quality main criteria of evaluation: efficacy


Eligibility criteria:
inclusion criteria: 1. chronic stable symptomatic maculopapulous cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement and a positive darier's sign 2. age between 18 and 65 years. 3. female patients must be using a highly effective method of birth control (such as implants, injectables, combined oral contraceptives, some iuds, sexual abstinence, vasectomised partner), or they must be postmenopausal, surgically sterilised, or hysterectomised. 4. voluntarily signed written informed consent. exclusion criteria: 1. the presence of permanent severe diseases, especially those affecting the immune system, except for mastocytosis 2. history or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia 3. history or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy, hyper-/hypokalemia, bradycardia \ 440ms 4. evidence of severe renal dysfunction (creatinine \> 1,5 x upper reference value) 5. evidence of significant hepatic disease (liver enzymes \> 2 x upper reference value) 6. history of adverse reactions to rup, or other ingredients of the imp 7. presence of active cancer which requires chemotherapy or radiation therapy 8. aggressive systemic mastocytosis 9. history or presence of alcohol abuse or drug addiction 10. participation in any clinical trial within 4 weeks prior to enrolment 11. commitment to an institution in terms of § 40 abs. 1 s. 3 nr. 4 amg 12. intake of antihistamines or leukotriene antagonists within 7 days prior to the beginning of the study 13. intake of oral corticosteroids within 14 days prior to the beginning of the study 14. use of depot corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the study 15. pregnancy or breast-feeding

Keywords: assessment of wheal and flare development assessment of life quality